HRA CORPORATE RISK REGISTER: Risks 12 and above accepted by EMT

Version Control	Version	Feb-14	Board	Stephen Tebbutt	Date	18/02/2014

HRA Risk Ref	Dept. Risk Ref	Risk Type	Date raised	Last Reviewed	Risk Description	Timing	Likelihood	Impact	RAG Status & Trend	Status Change since last Report	Risk Owner	Risk Mitigation & Intended Impact	Action Owner	Due date for actions	Target residual risk RAG status	Impacted Projects /Areas	Escalated	Assurance sources
HRA004	IMG 9 (HRA004)	Formerly IMG	03/05/2013	Feb' 14	Risk: HRA unable to deliver to the level of expectation of stakeholders within its role to promote transparency in research Cause: Timescales of moving forward with stakeholders, interdependency of work streams, capacity and environment appetite for change whilst not disadvantaging UK Effect: Reputation of HRA damaged	Medium	3	4	12	†	TS	Extensive engagement and position statement prepared in collaboration with stakeholders	JW	On-going	6	Business Plan		
HRA005	IMG 10 (HRA005)	Formerly IMG	03/05/2013	Feb' 14	Risk: HRA led roles to improve research transparency in the UK perceived to make the UK a less attractive place to do research. Cause: Transparency work 'appearing' to restrict researchers, increase 'red-tape' and /or research burdens Effect: Reputation of HRA damaged with decrease in amount of research taking place in UK	Medium	3	4	12	\(TS	Extensive engagement and proportionate approach agreed. Need to maintain effective communications and engagement recognised	JW	On-going	6	Business Plan		
HRA010	SDB 8	SDB Part A	Oct '13 Meeting		Risk – Actual costs of open service are higher than the budget identified Cause – Open service SLA not finalised or costs agreed Effect – Limited resources not available for HRA objectives	Immediate	5	3	15	\(TC	This issue has been highlighted at HRA/ Sponsor meetings and successful meetings have been held to progress SLA, clarify costs, negotiate down between DH IT and HRA.	TS	Mar'14	3			Finance reports
HRA007	CDMG1	CDMG	02/04/2013	18/12/13 APB	Risk: implementation of HRA Assessment is high profile deliverable, with wide-spread assumptions that the proposals are implementable. Cause: AMS report and high profile researchers have been requesting a 'single R&D approval' for many years. Effect: Significant reputational risk to HRA, with risk of increase during delay to decision	imminent	4	5	15	\(-	Wide stakeholder involvement in development of proposals. Wide engagement and communication during testing and decision-making. Publication of feasibility study report and business case.	JMe	ongoing		HRA Assessment	escalated to EMG Dec 2013	C&D Steering Group